• Species Reactivity

  Human

• Specificity

  Detects human Kallikrein 2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human Kallikrein 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or B1 is observed.

• Source

  Monoclonal Mouse IgG    ₁ Clone # 426723

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human Kallikrein 2    
  Ile25-Pro261    
  Accession # P20151

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  1 µg/mL

  Recombinant Human Kallikrein 2 (Catalog # ).

• 
  

• Immunoprecipitation

  25 µg/mL

  Conditioned cell culture medium spiked with Recombinant Human Kallikrein 2 (Catalog # ),

• 
  

• Neutralization

  Measured by its ability to neutralize Recombinant Human Kallikrein 2 (2 µg/mL, Catalog # ) cleavage of the fluorogenic peptide substrate PFR-AMC (0.1 mM). The Neutralization Dose (ND    ₅₀) is typically 3.4 µg/mL.

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Kallikrein 2

Kallikrein 2 (KLK2) is a secreted serine protease that is highly expressed in the human prostate gland (1). It is also known as the prostate-specific glandular kallikrein. The enzyme is highly specific for cleavage after arginine residues. KLK2 is able to activate the urokinase-type plasminogen activator (2). KLK2 is inhibited by serpins such as protein C inhibitor, antichymotrypsin, and plasminogen activator inhibitor 1 (3‑5). KLK2 is structurally related to KLK3, the prostate-specific antigen (PSA). Like PSA, KLK2 is considered to be a biomarker for prostate cancer (6).

• References:

1. Chapelaine, P. et al. (1988) FEBS Lett. 236:205.

2. Frenette, G. et al. (1997) Int. J. Cancer 71:897.

3. Deperthes, D. et al. (1995) Biochim. Biophys. Acta 1245:311.

4. Grauer, L.S. et al. (1998) J. Androl. 19:407.

5. (1999) Cancer Res. 59:3927.

6. Sardana, G. et al. (2008) Clin. Chem. 54:1951.

• Entrez Gene IDs:

  3817 (Human); 24841 (Rat)

• Alternate Names:

  EC 3.4.21; EC 3.4.21.35; glandular kallikrein 2; Glandular kallikrein-1; hGK-1; hK2; Kallikrein 2; kallikrein 2, prostatic; kallikrein-2; kallikrein-related peptidase 2; Klk1c2; KLK2; KLK2A2; MGC12201; Tissue kallikrein-2; Ton